XETRA - Delayed Quote EUR

BioNxt Solutions Inc. (BXT.DE)

0.2630

-0.0100

(-3.66%)

At close: January 10 at 5:35:44 PM GMT+1

BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP

BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the expansion of its intellectual property portfolio with the filing ...

ACCESSWIRE 24 days ago

BNXTF
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment

VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development ...

ACCESSWIRE last month

BNXTF
BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide

BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, announces the development of a sublingual thin-film oral dissolvable film (ODF) for Semaglutide, ...

ACCESSWIRE last month

BNXTF
BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity

BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce the expansion of its next-generation product pipeline. This includes proprietary Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral ...

ACCESSWIRE last month

BNXTF
BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

VANCOUVER, BC / ACCESSWIRE / October 29, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce that it has initiated the nationalization process for the filing of a family of patents for ...

ACCESSWIRE 2 months ago

BNXTF
Terry Lynch Joins BioNxt as Capital Markets Advisor

VANCOUVER, BC / ACCESSWIRE / October 7, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce that Terry Lynch has joined the BioNxt team as a capital markets advisor. Mr. Lynch brings ...

ACCESSWIRE 3 months ago

BNXTF
BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities

VANCOUVER, BC / ACCESSWIRE / September 26, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to provide an update on its flagship sublingual Cladribine drug formulation program for the treatment ...

ACCESSWIRE 3 months ago

BNXTF
BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

VANCOUVER, BC / ACCESSWIRE / September 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to report that the European Patent Office ("EPO") has issued a positive international examination report ...

ACCESSWIRE 4 months ago

BNXTF
BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations

VANCOUVER, BC / ACCESSWIRE / August 15, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a non-binding letter of intent (the "LOI") with German-based international contract ...

ACCESSWIRE 4 months ago

BNXTF
BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development

VANCOUVER, BC / ACCESSWIRE / July 17, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a statement of work ("SOW") with a German-based international contract research, ...

ACCESSWIRE 5 months ago

BNXTF
BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization

VANCOUVER, BC / ACCESSWIRE / July 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a master services agreement ("MSA") with a German-based international contract research, ...

ACCESSWIRE 6 months ago

BNXTF
BioNxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / June 19, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce ...

ACCESSWIRE 6 months ago

BNXTF
BioNxt Solutions Announces ODF Cladribine Update and Financing

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / April 25, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce ...

ACCESSWIRE 8 months ago

BNXTF
BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps

VANCOUVER, BC / ACCESSWIRE / March 18, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that based on the recent success of its toxicity and comparative pharmacokinetic ("PK") studies the ...

ACCESSWIRE 9 months ago

BNXTF
BioNxt Reports Successful Results From ODF Cladribine PK Study

VANCOUVER, BC / ACCESSWIRE / March 13, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that the comparative pharmacokinetic ("PK") study for its oral dissolvable film ("ODF") based proprietary ...

ACCESSWIRE 9 months ago

BNXTF
BioNxt Reports Completion of ODF Cladribine PK Study

VANCOUVER, BC / ACCESSWIRE / March 4, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that the comparative pharmacokinetic ("PK") study for its oral dissolvable film ("ODF") based proprietary ...

ACCESSWIRE 10 months ago

BNXTF
BioNxt Solutions Finalizes Agreement

VANCOUVER, BC / ACCESSWIRE / February 16, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that it has finalized and executed a settlement agreement (the "Settlement Agreement") with ...

ACCESSWIRE 10 months ago

BNXTF
BioNxt Reports Successful Results From ODF Cladribine Toxicity Study

VANCOUVER, BC / ACCESSWIRE / February 7, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that the toxicity study for its oral dissolvable film ("ODF") based proprietary Cladribine product ...

ACCESSWIRE 10 months ago

BNXTF
BioNxt Solutions Announces Closing of Final Tranche of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / January 29, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) is pleased to announce ...

ACCESSWIRE 11 months ago

BNXTF

Performance Overview

Return	BXT.DE	S&P/TSX Composite index
YTD	-2.95%	+0.60%
1-Year	-43.44%	+18.10%
3-Year	-65.62%	+17.47%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioNxt Solutions Inc. (BXT.DE)

BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP

BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment

BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide

BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity

BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

Terry Lynch Joins BioNxt as Capital Markets Advisor

BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities

BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations

BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development

BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization

BioNxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement

BioNxt Solutions Announces ODF Cladribine Update and Financing

BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps

BioNxt Reports Successful Results From ODF Cladribine PK Study

BioNxt Reports Completion of ODF Cladribine PK Study

BioNxt Solutions Finalizes Agreement

BioNxt Reports Successful Results From ODF Cladribine Toxicity Study

BioNxt Solutions Announces Closing of Final Tranche of Non-Brokered Private Placement

Performance Overview